Valuation: Proteomics International Laboratories Ltd

Market Cap 19M 13.35M 11.59M 10.85M 9.92M 18.72M 1.27B 127M 49.82M 637M 50.13M 49.04M 2.12B P/E 2024
-17.4x
P/E 2025 -5.38x
Enterprise Value 8.24M 5.79M 5.02M 4.71M 4.3M 8.12M 551M 55.04M 21.6M 276M 21.74M 21.27M 918M EV / Sales 2024
33.2x
EV / Sales 2025 12.8x
Free-Float
74.56%
Yield 2024 *
-
Yield 2025 -
1 day+3.13%
1 week+10.00%
Current month+13.79%
1 month-17.50%
3 months-31.25%
6 months-64.13%
Current year-74.81%
1 week 0.14
Extreme 0.135
0.16
1 month 0.14
Extreme 0.135
0.22
Current year 0.1
Extreme 0.098
0.86
1 year 0.1
Extreme 0.098
0.86
3 years 0.1
Extreme 0.098
1.4
5 years 0.1
Extreme 0.098
1.4
10 years 0.1
Extreme 0.098
1.48
Manager TitleAgeSince
Chief Executive Officer - 2026-01-18
Director of Finance/CFO - 2026-04-16
Director of Finance/CFO - 2021-07-11
Director TitleAgeSince
Director/Board Member - 2017-11-21
Chairman 56 -
Director/Board Member - 2024-11-07
Date Insider Type Main position Quantity % Market Cap.
11/21/24 Free

Founder

800,000 0.6107%
11/21/24 Free

Founder

800,000 0.6107%
11/21/24 Free

Founder

1,000,000 0.7633%
Change 5-day change 1-year change 3-year change Capi.($)
+3.12%+10.00%-54.17%-80.24% 18.65M
-3.25%+12.81%+52.96%+88.86% 64.9B
+0.69%-2.81%+25.84%+68.41% 54.05B
-1.07%-1.89%-17.90%-14.36% 23.16B
+33.86%+28.54%+18.76%+502.77% 21.46B
+1.87%+5.08%+29.88%-7.94% 21.25B
-0.79%+0.54%+31.17%-25.84% 17.94B
-3.37%+19.44%+211.98%+369.13% 17.03B
+3.29%+2.09%+17.32%+586.49% 14.99B
-7.94%-5.66%+39.35%+157.52% 14.25B
Average -0.62%+3.70%+35.52%+164.48% 24.9B
Weighted average by Cap. -1.07%+3.64%+41.94%+146.99%

Financials

2024 2025
Net sales 3.28M 2.3M 2M 1.87M 1.71M 3.23M 219M 21.89M 8.59M 110M 8.65M 8.46M 365M 3.31M 2.33M 2.02M 1.89M 1.73M 3.26M 221M 22.13M 8.69M 111M 8.74M 8.55M 369M
Net income -6.38M -4.48M -3.89M -3.64M -3.33M -6.28M -426M -42.6M -16.72M -214M -16.83M -16.46M -710M -8.11M -5.7M -4.95M -4.64M -4.24M -8M -543M -54.22M -21.28M -272M -21.42M -20.95M -904M
Net Debt -6.32M -4.45M -3.86M -3.61M -3.3M -6.23M -423M -42.25M -16.58M -212M -16.69M -16.33M -705M -10.76M -7.56M -6.56M -6.15M -5.62M -10.6M -719M -71.89M -28.22M -361M -28.39M -27.78M -1.2B
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-
Date Price Change Volume
26-08-06 A$0.1650 +3.13% 51,897
26-08-05 A$0.1600 +14.29% 257,057
26-08-04 A$0.1400 +3.70% 166,898
26-08-03 A$0.1350 -6.90% 164,178
26-07-31 A$0.1450 0.00% 31,370

Annual profits - Rate of surprise